Saturday 17 October 2026 Export AURA’s income statement to Excel — free account

Aura Biosciences, Inc.

In the quarter to June 2026, EPS fell 2.13% and free cash flow fell 56.3%, each against the same quarter a year earlier.

6.10 0.24 −3.79%

Follow AURA

Alert me

Market cap: $657.5M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 39.92

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	2	5	—	1	1	1	—	—	—	—

Insider Ownership 29.84%

Capital & Financial Ratios $m

Market Cap 657.49

Revenue —

Net Income (131.01)

Free Cash Flow (103.35)

Net Debt (323.84)

Current Ratio 16.82

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 1.84

Past 5Y EPS Growth —

This Y EPS Growth 5.38%

Next Y EPS Growth 8.84%

Next Y revenue growth —

Next 5Y EPS Growth 12.07%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 21.53%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	226	151	144	324
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	232	161	150	329

	2023	2024	2025	Q'26
Payables	2	2	2	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	12	15	18	20

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(11.21%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(30)	(33)	—	—	—
’25	(23)	(21)	(20)	(20)	(85)
’24	(24)	(16)	(15)	(24)	(80)
’23	(16)	(15)	(15)	(17)	(64)
’22	(15)	(11)	(11)	(18)	(55)
’21	(5)	(6)	(9)	(12)	(32)
’20	(8)	(6)	(21)	(4)	(24)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(30)	(33)	—	—	—
’25	(24)	(21)	(20)	(21)	(85)
’24	(25)	(17)	(16)	(24)	(81)
’23	(17)	(15)	(15)	(18)	(65)
’22	(16)	(11)	(11)	(18)	(56)
’21	(5)	(7)	(9)	(13)	(35)
’20	(8)	(6)	(21)	(4)	(25)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.50)	(0.48)	—	—	—
’25	(0.55)	(0.47)	(0.40)	(0.37)	(1.76)
’24	(0.40)	(0.41)	(0.42)	(0.52)	(1.75)
’23	(0.46)	(0.48)	(0.48)	(0.50)	(1.93)
’22	(0.44)	(0.46)	(0.54)	(0.52)	(1.96)
’21	(14.82)	(20.23)	(28.33)	48.26	(8.95)
’20	(0.32)	(0.28)	(9.64)	—	(60.51)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	13.50	9.43	5.99	6.63	4.35	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	26.16	24.83	13.50	12.38	8.60
People
People	Employees	—	—	—	—	42	52	72	89	109	113
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	0.00	0.00	0.00	0.00	—	—	—
	EBT	—	—	—	(24)	(22)	(35)	(59)	(76)	(87)	(106)
	EBT margin, %	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	—	(24)	(22)	(35)	(59)	(76)	(87)	(106)
	Depreciation	—	—	—	1	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	(1.03)	(60.51)	(8.95)	(1.96)	(1.93)	(1.75)	(1.76)
	Cash flow	—	—	—	(0.71)	(66.27)	(6.28)	(1.82)	(1.61)	(1.61)	(1.40)
	Capex	—	—	—	0.00	(2.10)	(0.41)	(0.04)	(0.02)	(0.03)	(0.01)
	Free cash flow	—	—	—	(0.71)	(68.37)	(6.69)	(1.86)	(1.63)	(1.63)	(1.41)
	Book value	—	—	—	1.05	(296.22)	29.52	6.53	5.70	3.06	2.27
	Shares, m	—	—	—	29	0	5	30	40	50	60
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(21)	(24)	(32)	(55)	(64)	(80)	(85)
	Capex	—	—	—	(2)	(1)	(2)	(1)	(1)	(1)	0
	Free cash flow	—	—	—	(21)	(25)	(35)	(56)	(65)	(81)	(85)
Balance, $m
Balance, $m	Working capital	—	—	—	27	16	146	186	219	146	131
	Total debt	—	—	—	0	0	1	21	—	—	—
	Net debt	—	—	—	(32)	(17)	(149)	(189)	(226)	(151)	(144)
	Shareholders’ equity	—	—	—	31	(109)	152	196	226	152	137
Returns, %
Returns, %	ROA	—	—	—	(163.16)	(101.87)	(50.72)	(30.61)	(31.90)	(39.73)	(60.35)
	ROIC	—	—	—	0.00	0.00	(682.29)	(558.12)	0.00	(6,857.59)	0.00
	ROE	—	—	—	30.83	30.73	(211.88)	(33.78)	(36.26)	(46.01)	(73.52)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ANNX Annexon, Inc.	$682.5M	— (loss-making)	—	—	n/m	−26.41% (below 0%: shrinking)	0.00%	0.00%	Compare
MDXG MiMedx Group, Inc	$682.2M	111×	— (loss-making)	−34.73% (below 0%: shrinking)	n/m	−174.83% (below 0%: shrinking)	68.96%	(28.69%)	Compare
CADL Candel Therapeutics, Inc.	$681.8M	— (loss-making)	— (loss-making)	0.00%	n/m	−93.35% (below 0%: shrinking)	0.00%	0.00%	Compare
PHAR Pharming Group N.V. Sponsored ADR	$681.6M	62.4×	— (loss-making)	−3.22% (below 0%: shrinking)	−57.14% (below 0%: shrinking)	−183.87% (below 0%: shrinking)	83.92%	1.44%	Compare
GYRE Gyre Therapeutics, Inc.	$678.6M	— (loss-making)	— (loss-making)	−2.12% (below 0%: shrinking)	n/m	−130.45% (below 0%: shrinking)	92.41%	(49.35%)	Compare
AURA Aura Biosciences, Inc.	$657.5M	— (loss-making)	—	—	n/m	−56.26% (below 0%: shrinking)	0.00%	0.00%
DSGN Design Therapeutics, Inc.	$655.9M	— (loss-making)	— (loss-making)	—	n/m	−7.00% (below 0%: shrinking)	0.00%	0.00%	Compare
PRME Prime Medicine, Inc.	$654.8M	— (loss-making)	— (loss-making)	+3.50% (above 0%: growing)	n/m	+4.40% (above 0%: growing)	100.00%	(3,750.87%)	Compare
AVTX Avalo Therapeutics, Inc.	$644.1M	— (loss-making)	— (loss-making)	−70.14% (below 0%: shrinking)	n/m	+75.70% (above 0%: growing)	55.73%	0.00%	Compare
Median of peers	$680.1M	—	—	−2.67%	—	−59.88%	62.35%	0.00%

All 614 Biotechnology stocks →

Aura Biosciences, Inc. (AURA) key facts

Aura Biosciences, Inc. (AURA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, AURA traded at $6.10, a market capitalization of $657.5 million.
Return on equity was −73.5% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.